Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Enfuvirtide (Fuzeon) vs Teduglutide (Gattex)
An educational, source-based comparison of Enfuvirtide (Fuzeon) and Teduglutide (Gattex) — how each peptide works, what it's researched for, and what to know before going deeper.
36-amino-acid peptide that binds the gp41 subunit of HIV-1 envelope, blocking the conformational change required for viral-host membrane fusion and cell entry.
- Treatment-experienced HIV-1 infection
- • FDA-approved.
- • Injection-site reactions nearly universal.
GLP-2 analog for short bowel syndrome dependent on parenteral support.
Recombinant analog of glucagon-like peptide-2 with alanine→glycine substitution at position 2, resisting DPP-IV degradation; promotes intestinal mucosal growth, villus height, and absorptive capacity.
- Short bowel syndrome with intestinal failure
- Reduction of parenteral nutrition dependence
- • FDA-approved.
- • Colorectal polyp surveillance required.
- • Risk of intestinal obstruction and biliary/pancreatic disease.
Enfuvirtide (Fuzeon) vs Teduglutide (Gattex) — Key differences
- Class: Enfuvirtide (Fuzeon) is classified as Fusion Inhibitor · Antiviral, while Teduglutide (Gattex) is GLP-2 Analog · Gastrointestinal.
- Primary research focus: Enfuvirtide (Fuzeon) — treatment-experienced hiv-1 infection; Teduglutide (Gattex) — short bowel syndrome with intestinal failure.
- Tag: FDA-Approved · Antiviral vs FDA-Approved · GI.